Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    114
    ...
ATC Name B/G Ingredients Dosage Form Price
A02BC04 RAZOLE 20 G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 639,925 L.L
A11CC05 VITEX D3 G Vitamin D3 - 10,000IU 10,000IU Capsule 447,500 L.L
B03AB05 ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 50mg/ml 50mg/ml Drops 459,594 L.L
B05D CAPD/DPCA 19Solution for peritoneal dialysis sleep safe G Sodium chloride - 5.786g/l, Sodium-(S)-lactate - 3.925g/l, Calcium chloride 2H2O - 0.1838g/l, Magnesium chloride, 6H2O - 0.1017g/l, Anhydrous glucose - 22.73g/l, Fructose , - up to 1.1g/l Injectable solution 744,140 L.L
C09CA07 NIZORTAN G Telmisartan - 40mg 40mg Tablet 455,563 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 749,058 L.L
D10AF02 MED-ERYTHROMYCIN 4% G Erythromycin - 40mg/ml 4% Solution 235,492 L.L
J01DB05 ROXIL G Cefadroxil (monohydrate) - 500mg 500mg Capsule 869,466 L.L
J01MA12 LOXAMOX G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 747,176 L.L
L01EF01 PAPILLIO G Palbociclib - 100mg 100mg Capsule, hard 147,883,080 L.L
N03AX12 GABAPENTINE ARROW GENERIQUES G Gabapentin - 300mg 300mg Capsule 1,342,499 L.L
N05CM18 DEXMEDETOMIDINE EVER PHARMA G Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable concentrate for solution 9,340,433 L.L
P03AB02 GAMMAPHARM G Lindane - 1% 1% Shampoo 195,817 L.L
R06AB52 HISTAMED-F G Dexchlorpheniramine maleate - 2mg, Dexamethasone - 0.25mg, Fluphenazine HCl - 0.25mg Tablet, coated 579,772 L.L
A11CC05 VIT-X-FORTE G Vitamin D3 - 10,000IU 10,000IU Capsule 895,895 L.L
C09CA07 TELMICARD 40 G Telmisartan - 40mg 40mg Tablet 659,123 L.L
C10AA07 SINLIP G Rosuvastatin (calcium) - 20mg 20mg Tablet, film coated 563,070 L.L
D10AF02 ERYTHROMYCIN 1.5 % G Erythromycin - 15mg/ml 1.5 % Solution 501,701 L.L
G04BX14 DEPOJOY G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,565,577 L.L
J01MA12 PILOQ G Levofloxacin - 500mg/100ml 500mg/100ml Injectable solution 980,365 L.L
M01AC02 REUTENOX G Tenoxicam - 20mg 20mg Tablet, coated 576,508 L.L
N01BB54 PRILA G Prilocaine - 2.5% w/w, Lidocaine - 2.5% w/w Cream 1,057,604 L.L
N03AX12 GABAPENTINE ARROW GENERIQUES G Gabapentin - 300mg 300mg Capsule 1,342,499 L.L
N05CM18 PROXIDA G Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable concentrate for solution 1,771,184 L.L
P03AB02 GAMMA BENZENE HEXACHLORIDE G Lindane - 1% 1% Lotion 167,660 L.L
A11CC05 ALTUM G Vitamin D3 - 50,000IU 50,000IU Capsule, hard 712,620 L.L
C09CA07 TOLURA G Telmisartan - 40mg 40mg Tablet 532,162 L.L
C10AA07 SUPERSTAT G Rosuvastatin (calcium) - 20mg 20mg Tablet, coated 517,379 L.L
D10AF02 SPOTEX G Erythromycin - 4% 4% Gel 854,684 L.L
G04BX14 LEJAM G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,269,931 L.L
    ...
    114
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025